A clinical-stage biopharmaceutical company focused on developing oncological therapies to improve patient outcomes.

Carrick Therapeutics

Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour.
Targeting the molecular pathways that drive the most aggressive and resistant forms of cancer will transform the way that cancer is treated and have a major impact on the lives of cancer patients. By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, Carrick will streamline the introduction of these ground-breaking cancer therapies into the clinic, thus serving cancer patients around the world.

Woodford Investment Management

Lightstone Ventures

Cambridge Innovation Capital

Evotec

University of Cambridge Enterprise

ARCH Venture Partners

Google Ventures

Pfizer

Revelation Partners

Rosetta Capital

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer

https://lnkd.in/eTajEtpM

Delighted to announce a First Patient Dosed in our Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer. 

https://lnkd.in/e8deVH6g

Great interview on Oncology Tube with our CMO Stuart McIntosh talking about our ongoing Phase 2 study SUMIT-ELA, combining samuraciclib and elacestrant in patients with CDK4/6i resistant HR+,HER2- metastatic breast cancer in collaboration with Menarini. 

https://lnkd.in/ezt5ZqWW

Delighted to announce US FDA clearance of our IND for CT7439, a First In Class Inhibitor of CDK12/13. Carrick's second therapeutic candidate which further strengthens our oncology pipeline.
https://lnkd.in/e7WuT_9v

Metric
Company Name	Carrick Therapeutics
Symbol
MSH ID	COM:CARRICKTHERAPEUTICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	19
Website	carricktherapeutics.com
LinkedIn	carrick-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CARRICKTHERAPEUTICS

Carrick Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue